MSMathew E. Sowa

Mathew E. Sowa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mathew E. Sowa has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance

    by Bridget T. Kreger, Yanke Liang, Nicole M. Reilly, Meghan E. Spears, William A. Scott, Jeffrey R. Simard, Ping Li, Prasoon Chaturvedi, Roman V. Agafonov, Jacob Stephenson, et al.

    Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer–driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by developing CFT1946, a potent, orally bioavailable, and brain-penetrant cereblon-based bifunctional degrader that targets BRAFV600-mutant protein while sparing wild-type RAF family members. CFT1946 demonstrated potent activity in preclinical models of BRAFV600-mutant driven melanoma and colorectal cancer while sparing wild-type MAPK signaling and mitigating the paradoxical activation associated with approved BRAFis. CFT1946 was efficacious in an intracranial BRAFV600E melanoma tumor model and demonstrated robust activity in multiple cellular and patient-derived BRAFV600-mutant melanoma and colorectal cancer models of acquired and adaptive RAF dimer–driven BRAFi resistance. CFT1946 therefore represents an effective therapeutic modality with the potential to overcome the key limitations of current BRAFV600-mutant targeted therapies. Significance: CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer–driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289


  • Open Access

    Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface

    by Uddhav K. Shigdel, Seung-Joo Lee, Mathew E. Sowa, Brian R. Bowman, Keith Robison, Minyun Zhou, Khian Hong Pua, Dylan T. Stiles, Joshua A. V. Blodgett, Daniel W. Udwary, et al.

    Significance: This manuscript reports on a member of the FK506/rapamycin family, WDB002, and the realization that FKBP-mediated recognition is a genetically programmable modality that enables engagement of topologically flat targets. FKBP-mediated recognition is thus nature’s strategy for drugging the “undruggable.” The surface of FKBP engages three completely unrelated targets—calcineurin, MTOR, and CEP250—with high-target affinity and specificity, using different constellations of amino acid residues. Target specificity is determined solely by the “variable domain” of the bound small molecule alone, suggesting the modality might be generalizable to other undruggable targets through variable domain engineering. Finally, since WDB002 targets CEP250, it may be a promising starting point for developing a treatment for COVID-19.